Subtopic Deep Dive
Immune Thrombocytopenic Purpura Pathophysiology
Research Guide
What is Immune Thrombocytopenic Purpura Pathophysiology?
Immune Thrombocytopenic Purpura (ITP) pathophysiology involves autoantibody-mediated platelet destruction primarily targeting glycoprotein IIb/IIIa and impaired megakaryopoiesis due to T-cell dysregulation.
ITP features antibodies against platelet glycoproteins leading to splenic macrophage phagocytosis via Fcγ receptors (Cines and Blanchette, 2002; 1332 citations). T-cell mediated effects impair thrombopoiesis, as detailed in molecular mechanisms of platelet production (Kaushansky, 2005; 564 citations). Recent reviews confirm antibody and T-cell roles in pathogenesis (Zufferey et al., 2017; 515 citations). Over 10 key papers span mechanisms and related disorders.
Why It Matters
Understanding ITP pathophysiology enables targeted therapies like thrombopoietin receptor agonists, as evidenced by multilineage responses in related refractory anemias (Olnes et al., 2012; 523 citations). It differentiates ITP from thrombotic microangiopathies, guiding precise management (Scully et al., 2016; 482 citations). ASH guidelines rely on these mechanisms for treatment recommendations (Neunert et al., 2019; 1218 citations), improving pediatric and adult outcomes (Cines and Blanchette, 2002).
Key Research Challenges
Heterogeneity in Autoantibody Targets
ITP autoantibodies vary across patients, complicating uniform models (Cines and Blanchette, 2002). Glycoprotein IIb/IIIa is primary, but others contribute variably. Zufferey et al. (2017) highlight inconsistent antibody detection in cohorts.
T-Cell Dysregulation Mechanisms
T-cell roles in megakaryocyte suppression remain incompletely mapped (Zufferey et al., 2017). Kaushansky (2005) details thrombopoietin regulation disrupted in ITP. Cohort studies show variable T-cell profiles.
Distinguishing from Microangiopathies
Overlaps with TTP/APS challenge differential diagnosis (Scully et al., 2016). Endothelial roles blur lines (van Hinsbergh, 2011). Consensus criteria aid but require pathophysiological clarity (Miyakis et al., 2006).
Essential Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
Spiros Miyakis, Michael D. Lockshin, Tatsuya Atsumi et al. · 2006 · Journal of Thrombosis and Haemostasis · 7.0K citations
BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTOR
J. Evan Sadler · 1998 · Annual Review of Biochemistry · 1.4K citations
Von Willebrand factor (VWF) is a blood glycoprotein that is required for normal hemostasis, and deficiency of VWF, or von Willebrand disease (VWD), is the most common inherited bleeding disorder. V...
Immune Thrombocytopenic Purpura
Douglas B. Cines, Victor S. Blanchette · 2002 · New England Journal of Medicine · 1.3K citations
Immune thrombocytopenic purpura, which may lead to bleeding, is typically caused by antibodies directed against the platelet glycoprotein IIb/IIIa complex. Since the management of the disorder is d...
American Society of Hematology 2019 guidelines for immune thrombocytopenia
Cindy Neunert, Deirdra R. Terrell, Donald M. Arnold et al. · 2019 · Blood Advances · 1.2K citations
Abstract Background: Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physician...
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Flora Peyvandi, Marie Scully, Johanna A. Kremer Hovinga et al. · 2016 · New England Journal of Medicine · 634 citations
Caplacizumab induced a faster resolution of the acute TTP episode than did placebo. The platelet-protective effect of caplacizumab was maintained during the treatment period. Caplacizumab was assoc...
The molecular mechanisms that control thrombopoiesis
K Kaushansky · 2005 · Journal of Clinical Investigation · 564 citations
Our understanding of thrombopoiesis--the formation of blood platelets--has improved greatly in the last decade, with the cloning and characterization of thrombopoietin, the primary regulator of thi...
Endothelium—role in regulation of coagulation and inflammation
Victor W.M. van Hinsbergh · 2011 · Seminars in Immunopathology · 557 citations
By its strategic position at the interface between blood and tissues, endothelial cells control blood fluidity and continued tissue perfusion while simultaneously they direct inflammatory cells to ...
Reading Guide
Foundational Papers
Start with Cines and Blanchette (2002; 1332 citations) for core antibody mechanisms against GPIIb/IIIa. Follow with Kaushansky (2005; 564 citations) on thrombopoiesis regulation disrupted in ITP.
Recent Advances
Study Zufferey et al. (2017; 515 citations) for T-cell integration; Neunert et al. (2019; 1218 citations) for guideline-implied mechanisms; Scully et al. (2016; 482 citations) for microangiopathy contrasts.
Core Methods
Antibody detection via flow cytometry; thrombopoietin ELISA; cohort platelet counts; mouse FcγR knockout models (Cines and Blanchette, 2002; Kaushansky, 2005).
How PapersFlow Helps You Research Immune Thrombocytopenic Purpura Pathophysiology
Discover & Search
Research Agent uses searchPapers and citationGraph on 'Immune Thrombocytopenic Purpura' to map Cines and Blanchette (2002; 1332 citations) as foundational, revealing 10+ related papers like Zufferey et al. (2017). exaSearch uncovers cohort studies on FcγR polymorphisms; findSimilarPapers expands to TTP differentiations (Scully et al., 2016).
Analyze & Verify
Analysis Agent applies readPaperContent to extract autoantibody targets from Cines and Blanchette (2002), then verifyResponse with CoVe checks claims against Neunert et al. (2019) guidelines. runPythonAnalysis performs statistical verification on platelet count data from ASH cohorts, with GRADE grading for evidence strength in T-cell mechanisms (Zufferey et al., 2017).
Synthesize & Write
Synthesis Agent detects gaps in T-cell therapy links via contradiction flagging across Kaushansky (2005) and Zufferey et al. (2017). Writing Agent uses latexEditText, latexSyncCitations for ITP mechanism reviews, latexCompile for figures, and exportMermaid for thrombopoiesis pathway diagrams.
Use Cases
"Extract platelet count statistics from ITP cohorts in ASH guidelines and plot trends."
Research Agent → searchPapers('ASH ITP guidelines') → Analysis Agent → readPaperContent(Neunert et al., 2019) → runPythonAnalysis(pandas aggregation, matplotlib survival curves) → researcher gets CSV export of response rates by age group.
"Write LaTeX review on ITP autoantibody mechanisms citing Cines 2002."
Synthesis Agent → gap detection on pathogenesis → Writing Agent → latexEditText(structured abstract) → latexSyncCitations(Cines and Blanchette, 2002; Zufferey et al., 2017) → latexCompile → researcher gets compiled PDF with bibliography.
"Find code for simulating ITP thrombopoiesis models from recent papers."
Research Agent → searchPapers('ITP megakaryopoiesis model') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(Kaushansky-related sims) → researcher gets annotated repo with thrombopoietin dynamics code.
Automated Workflows
Deep Research workflow scans 50+ papers via citationGraph from Cines and Blanchette (2002), generating structured reports on autoantibody vs. T-cell dominance. DeepScan applies 7-step CoVe to verify mechanisms in Zufferey et al. (2017) against guidelines (Neunert et al., 2019). Theorizer builds hypotheses on FcγR polymorphisms from cohort data chains.
Frequently Asked Questions
What defines ITP pathophysiology?
Autoantibody-mediated destruction of platelets via Fcγ receptors on macrophages and impaired megakaryopoiesis from T-cell effects (Cines and Blanchette, 2002; Zufferey et al., 2017).
What are key methods in ITP research?
Cohort studies measure anti-platelet antibodies; animal models test FcγR roles; thrombopoietin assays evaluate megakaryopoiesis (Kaushansky, 2005).
What are seminal papers on ITP?
Cines and Blanchette (2002; NEJM, 1332 citations) details antibody targets; Zufferey et al. (2017; 515 citations) covers T-cell mechanisms; Neunert et al. (2019; 1218 citations) links to guidelines.
What open problems exist in ITP pathophysiology?
Variable autoantibody targets across patients; precise T-cell suppression pathways; differentiation from APS/TTP (Miyakis et al., 2006; Scully et al., 2016).
Research Platelet Disorders and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Immune Thrombocytopenic Purpura Pathophysiology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Platelet Disorders and Treatments Research Guide